Aevi Genomic Medicine (GNMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2018 | 03-2018 | 12-2017 | 09-2017 | 06-2017 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -16,900 | -8,709 | -34,714 | -27,555 | -18,950 |
| Depreciation Amortization | 32 | 16 | 112 | 96 | 81 |
| Accounts payable and accrued liabilities | 520 | 742 | 806 | 3,344 | 1,744 |
| Other Working Capital | 884 | 701 | -2,044 | -127 | -1,406 |
| Other Operating Activity | 1,015 | 7 | 2,594 | -662 | 31 |
| Operating Cash Flow | $-14,449 | $-7,243 | $-33,246 | $-24,904 | $-18,500 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | 148 | 152 | N/A |
| Investing Cash Flow | $N/A | $0 | $148 | $152 | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 34 | 34 | 26,989 | 19 | 19 |
| Other Financing Activity | -163 | 0 | 0 | -145 | 0 |
| Financing Cash Flow | $-129 | $34 | $26,989 | $-126 | $19 |
| Beginning Cash Position | 33,729 | 33,729 | 39,838 | 39,838 | 39,838 |
| End Cash Position | 19,151 | 26,520 | 33,729 | 14,960 | 21,357 |
| Net Cash Flow | $-14,578 | $-7,209 | $-6,109 | $-24,878 | $-18,481 |
| Free Cash Flow | |||||
| Operating Cash Flow | -14,449 | -7,243 | -33,246 | -24,904 | -18,500 |
| Capital Expenditure | N/A | 0 | -4 | N/A | 0 |
| Free Cash Flow | -14,449 | -7,243 | -33,250 | -24,904 | -18,500 |